Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...

Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- ...

Inhibikase Therapeutics, Inc.’s IKT share price has surged by 18.46%, which has investors questioning if this is right time ...

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug ...

Jan 29 (Reuters) - Inhibikase Therapeutics (IKT.O), opens new tab said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.

Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and Inhibikase Therapeutics, Inc. (IKT) 10-day simple moving average is 2.65. Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and ...

BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of Mark Iwicki as the Company's Chief ...